2026年9月23日，泰格医药（03347）在香港联合交易所有限公司网站发布海外监管公告。公告称，香港交易及结算所有限公司及香港联合交易所有限公司对公告内容概不负责，并不对其准确性或完整性作出任何声明，且明确表示概不承担因依赖该等内容而产生的任何损失责任。
本次披露的文件已于深圳证券交易所网站同步刊登，供投资者参考。
公告显示，公司董事会组成如下： 1. 董事长：叶小平 2. 执行董事：叶小平博士、曹晓春女士、闻增玉先生 3. 职工董事：吴灝先生 4. 独立非执行董事：袁华刚先生、刘毓文女士、萧耀熙先生
泰格医药强调，此次公告的发布符合香港联交所证券上市规则第13.10B条的相关要求。公司将继续按照境内外监管规定，及时、准确地履行信息披露义务。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.